Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
BOSTON - Schering-Plough's (now Merck's) next-generation hepatitis C therapy narlaprevir may shape up as a better competitor for the Vertex hepatitis C drug telaprevir than Schering's first generation protease inhibitor boceprevir, if the ritonavir-boosted Phase IIa trial for narlaprevir stays true to the initial results